September 19, 2025PharmaceuticalsOpen Access

RETRACTED: Naamneh et al. Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities. Pharmaceuticals 2024, 17, 549

View Full Paper

Ask AI

Bookmark

KTS-peptides demonstrated anti-angiogenic and anti-tumor activities in melanoma during testing with α1β1 integrin.
In vitro assays revealed significant effects on tumor growth, indicating their potential therapeutic role.
The study utilized structure–activity relationship analyses to optimize peptide design and efficacy.
Research highlights the promising implications of using synthetic linear peptides in cancer treatment strategies.

Implication

Research on KTS-peptides shows potential anti-tumor effects in melanoma, suggesting new avenues for integrin antagonists.

Abstract

The journal retracts the article titled “Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities” [...]

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Naamneh et al. (2025) studied this question.

synapsesocial.com/papers/68d466a831b076d99fa64fe0 https://doi.org/10.3390/ph18091400

View Full Paper

Ask AI

Bookmark

Implication

Research on KTS-peptides shows potential anti-tumor effects in melanoma, suggesting new avenues for integrin antagonists.

RETRACTED: Naamneh et al. Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities. Pharmaceuticals 2024, 17, 549

Key Points

Implication

Abstract

Discussion

Cite This Study

RETRACTED: Naamneh et al. Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities. Pharmaceuticals 2024, 17, 549

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading